Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus SOX in locally advanced gastric cancer
NCT04367025Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2020
- Primary completion
- May 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Major Pathologic Response. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04367025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04367025.